Core Characteristics

• Live attenuated viral vaccine.
• Contains minimum 1000 infective units of attenuated virus per dose.
• Lacks preservatives, increasing susceptibility to bacterial contamination.
• Available as standalone, measles-rubella combination, or measles-mumps-rubella combination.

Composition And Strains

• Edmonston-Zagreb strain propagates on human diploid cell culture.
• Schwarz strain propagates in chick-embryo fibroblasts.
• Requires reconstitution with supplied sterile diluent prior to administration.

Administration And Storage

• Dose volume strictly measures 0.5 mL.
• Administered via subcutaneous route.
• Preferred site involves right upper arm at deltoid insertion or anterolateral thigh.
• Lyophilized powder requires storage between 2°C and 8°C.
• Highly sensitive to heat and light exposure.
• Reconstituted vaccine mandates discarding within 4 to 6 hours to prevent toxic shock syndrome from staphylococcal contamination.

Immunization Schedule

Universal Immunization Program

• Employs measles-rubella combination vaccine.

Indian Academy Of Pediatrics Guidelines

• Recommends measles-mumps-rubella formulation.

Catch-Up And Outbreak Protocols

• Outbreak administration permits early dosing at 6 months.
• Early outbreak dose remains uncounted; requires standard 9-month dose administration.
• Unimmunized children require two doses separated by minimum 4-week interval.
• Post-exposure prophylaxis utilizes measles-mumps-rubella vaccine within 72 hours of exposure in immunocompetent hosts.

Immunogenicity And Efficacy

• Single dose median vaccine effectiveness measures 84% at 9 to 11 months.
• Single dose median vaccine effectiveness increases to 92.5% beyond 12 months.
• Maternal antibody interference causes primary vaccine failure in 15% of infants vaccinated at 9 months.
• Second dose induces protective immunity in 95% of primary non-responders.

Adverse Effects And Contraindications

Adverse Reactions

• Minor local pain and tenderness occur within 24 hours.
• Mild fever develops in 5% to 15% of recipients 7 to 12 days post-vaccination.
• Transient macular rash appears 7 to 10 days post-vaccination in 2% of recipients.
• Rare complications include thrombocytopenic purpura occurring in 1 per 30,000 vaccinees.
• Toxic shock syndrome risk increases significantly if reconstituted vaccine exceeds 4-hour to 6-hour usage window.

Contraindications

• Severe immunocompromised states, including symptomatic human immunodeficiency virus.
• Systemic high-dose corticosteroid therapy exceeding 14 days.
• Pregnancy mandates strict avoidance.
• Recent receipt of immunoglobulin-containing blood products necessitates vaccination delay.